The CE mark registration for CentoMD® was successfully completed
Centogene is pleased to announce the successful completion of the CE mark registration for CentoMD®. The certificate was issued on April 28, 2015. CentoMD® was developed and produced utilizing the highest of regulatory standards – the CE label is the visible symbol that indicates that it complies with all applicable safety legislation and regulatory requirements.
Centogene is pleased to welcome you at our satellite symposium at this year's ESHG conference in Glasgow, June 7, 2015 to share our latest insights:
- Obtaining the highest accuracy in utilizing clinical evidence: The importance of mutation databases
- Case studies: The importance of clinical annotation and ethnic diversity
- Finding the needle in the "needle stack": Clinical filtering of variants in the era of big data explosion
Please register to our symposium to receive an extended trial access to CentoMD® here
Registrations are accepted on a first come - first serve basis.
Did you know...
...that in CentoMD® 10% of the variants published as clinically relevant are classified as neutral (benign) based on our available clinical data?
...that 50% of the clinically relevant variants in CentoMD® are newly detected at CENTOGENE?
...that CentoMD® is evidence based? Behind every variant is a clinical case diagnosed at CENTOGENE.
...that CentoMD® covers a worldwide cohort of patients and therefore provides the required breadth for proper interpretation?
...that CentoMD® is continuously updated upon new evidence obtained and growing?
...that CE mark registration was successfully completed for CentoMD®?
… that CentoMD® is the world´s largest clinically annotated mutation database for rare diseases?
Do you wish to know more? Obtain more information here or just try CentoMD® for free.
If you have any questions or comments, please do not hesitate to contact us.
Senior Director Strategic Communication